Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of oral IPN60130 in fibrodysplasia ossificans progressiva
2020-002858-24Phase 2Active
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of Fidrisertib in fibrodysplasia ossificans progressiva (FOP) (3 arms), sponsored by Clementia Pharmaceuticals Inc. Primary endpoint: Annualized change from baseline in heterotopic ossification volume. Started Nov 2020; status: active.
02
Drugs
Fidrisertib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on 2020-002858-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002858-24.